Biological E. has entered into a licensing agreement with Canada's Providence Therapeutics Holdings to manufacture its mRNA COVID-19 vaccine in India, the company said on Tuesday.
The company has a separate deal to produce about 600 million doses of Johnson & Johnson's COVID-19 shot annuallyAs per the statement issued by Biological E., it will run a clinical trial of Providence's vaccine in India and seek emergency use approval for it.Providence will sell up to 30 million doses of its mRNA vaccine, PTX-COVID19-B, to Biological E., and will also provide the necessary technology transfer of the shot, with a minimum production capacity of 600 million doses in 2022 and a target capacity of 1 billion doses.